Partner with the Macrophage-Directed Therapies Summit
The industry’s renowned 5th Macrophage-Directed Therapies Summit remains the only forum uniting industry leaders in this niche space to advance their unique challenges in preclinical, translational and clinical development to build best-in-class therapies.
As they continue to face challenges in preclinical models, target screening and validation, clinical trial design, CAR-M engineering and scalable manufacturing, this ever-growing space rely on robust partners and reliable solutions to support research efforts.
Seize the unique opportunity to showcase your expertise while creating and building valuable relationships with this exclusive group of senior decision-makers in a close-knit environment.
- Exhibit your capabilities and place your dedicated solution in front of an engaged audience to educate industry stakeholders on how you can streamline development
- Drive brand awareness to establish yourself as the go-to partner for macrophage developers to distinguish from competitors
- Secure a bespoke speaking opportunity to maximize exposure and place yourself at the forefront of the industry
To find out more about the 2024 summit, get in touch to discuss bespoke partnership opportunities tailored to your business needs.
Our 2023 Partners
genOway is a biotechnology company with over 20 years of expertise in the development of physiologically relevant preclinical models.
The company has developed a catalog of humanized, "off-the-shelf" immuno-oncology mouse and cell models to accelerate research into cancer pathophysiology and enable the evaluation of new therapeutic agents.
Founded in 1999, genOway currently operates in more than 28 countries with 380 academic institutions and 170 life science companies, including 17 of the top 20 pharmaceutical companies.